Du är här

2016-02-03

Biotec Pharmacon ASA: Biotec Pharmacon: Invitation to Q4 2015 presentation and Capital Markets Day

(Tromsø, 3 February 2016) Biotec Pharmacon ASA ("Biotec"), OSE:
BIOTEC) will host a Capital Markets Day (CMD) Thursday 11 February
2016, following the Q4 presentation.

Time: 08:30 - 11:00
Location: Hotel Continental, Stortingsgaten 24/26, 0117 Oslo
Breakfast will be served prior to the presentations. For practical
reasons, investors, analysts and journalists are encouraged to
register via email to ir@biotec.no by 8 February 2016.

Capital Markets Day agenda:
0830 - 0900 Q4 Presentation, Svein Lien, CEO
0905 - 0905 CMD Introduction, Svein Lien, CEO
0905 - 0925 SBG Scientific platform, Rolf Engstad, CSO
0925 - 1000 Woulgan, Stuart Devine, Marketing Director
1000 - 1015 Q&A
1015 - 1045 ArcticZymes, Jethro Holter, Managing Director
1045 - 1050 Closing remarks and outlook, Svein Lien, CEO
1050 - 1100 Q&A

The presentation material from Biotec's Capital Markets Day will be
made available from 08:00 through newsweb.no and www.biotec.no. The
presentations will be webcasted live and in replay on www.biotec.no.
It will be possible to post questions through webcast console

For additional information, please contact:

Børge Sørvoll, CFO
+47 95 29 01 87
borge.sorvoll@biotec.no

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS
and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and
markets novel immunomodulating products, including Woulgan®, a
premium priced product in the advanced wound care market. ArcticZymes
develops, produces and markets enzymes of marine origin used in
molecular DNA technologies and diagnostics, representing growth
markets where rapid technological developments are creating a strong
demand for new and improved enzymes.

-----------------------------------------------------------
http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=339295...
http://mb.cision.com/Main/1090/9906754/472009.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.